Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2021; 12(11): 1009-1022
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1009
Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
Jenny Isaksson, Henrik Green, Dimitrios Papantoniou, Linn Pettersson, Mats Anden, Johan Rosell, Elisabeth Åvall-Lundqvist, Nils Oskar Elander
Jenny Isaksson, Elisabeth Åvall-Lundqvist, Nils Oskar Elander, Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping 58185, Sweden
Henrik Green, Division of Drug Research, Department of Biomedical and Clinical Sciences, Linköping University, Linköping 58185, Sweden
Dimitrios Papantoniou, Linn Pettersson, Department of Oncology, Ryhov County Hospital, Jönköping 55305, Sweden
Mats Anden, Department of Oncology, Kalmar County Hospital, Kalmar 39244, Sweden
Johan Rosell, Regional Cancer Center Southeast Sweden, Linköping University, Linköping 58185, Sweden
Author contributions: Isaksson J, Green H, Åvall-Lundqvist E and Elander NO designed the study; Isaksson J acquired the patient data with the help of Papantoniou D, Pettersson L and Anden M at the respective sites; Isaksson J, Green H, Rosell J and Elander NO analyzed the data; Isaksson J, Green H and Elander NO drafted the first version of the manuscript; all authors helped develop the methodology and perform the investigation, and all read and approved the final manuscript.
Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Regional Ethics Review board in Linköping, Region Östergötland, Sweden, No. 2018/139–31.
Informed consent statement: Based on the retrospective and noninterventional nature of the study and the absence of publication of individual data, the ethics board did not consider it possible or necessary to obtain written informed consent.
Conflict-of-interest statement: None of the authors have any conflicts of interest to declare.
Data sharing statement: Additional data are available at reasonable request to the corresponding author.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nils Oskar Elander, MD, PhD, Doctor, Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping University Hospital, Linköping 58185, Sweden. nils.elander@liu.se
Received: March 23, 2021
Peer-review started: March 23, 2021
First decision: July 27, 2021
Revised: August 9, 2021
Accepted: October 18, 2021
Article in press: October 18, 2021
Published online: November 24, 2021
Core Tip

Core Tip: Two recent trials reported impressive outcomes when upfront docetaxel is added to androgen deprivation therapy in metastatic castration-sensitive prostate cancer (mCSPC). This study presents the outcome and safety of this treatment strategy in a real-world context of all eligible patients in the southeast region of Sweden. While the treatment is toxic in terms of febrile neutropenia and unplanned hospitalizations, the outcome and long-term prognosis appear similar in real life and randomized controlled trial contexts. Further implementation of upfront docetaxel in mCSPC in routine care is encouraged.